# RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

> **NCT05787327** · PHASE2 · UNKNOWN · sponsor: **Chinese University of Hong Kong** · enrollment: 96 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Chinese Herb
- **DIAGNOSTIC_TEST:** Placebo

## Key facts

- **NCT ID:** NCT05787327
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-25
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2023-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05787327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05787327, "RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05787327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*